Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600135077) titled 'A prospective, observational study on the efficacy and safety of ruxolitinib phosphate cream combined with autologous blood therapy in the treatment of non-segmental vitiligo' on Oct. 23.
Study Type: Observational study
Study Design:
Cross-sectional
Primary Sponsor: Guangzhou Institute of Dermatology
Condition:
Non-segmental vitiligo
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-10-24
Target Sample Size: Lorcotibine Phosphate Cream + Autologous Blood Therapy group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=349072...